Oxacillin and Cloxacillin Dosing for Staphylococcal Infections
For methicillin-susceptible staphylococcal infections, initiate IV oxacillin 8-12 g/24h divided into 3-4 doses (typically 2g every 4-6 hours), continue IV therapy for 1-2 weeks until clinically stable, then transition to oral cloxacillin or dicloxacillin 500mg every 6 hours with probenecid for a total treatment duration of 4-6 weeks depending on infection severity. 1, 2
Intravenous Oxacillin Dosing
The FDA-approved dosing for oxacillin varies by infection severity 2:
- Mild to moderate infections: 250-500 mg IV every 4-6 hours
- Severe infections: 1 gram IV every 4-6 hours (equivalent to 8-12 g/24h total)
For endocarditis specifically, guidelines recommend oxacillin 8-12 g/24h IV divided into 3-4 doses for at least 4 weeks for native valve endocarditis 1. If prosthetic material is involved, extend to 6-8 weeks with addition of rifampin and gentamicin 1.
Duration of IV Therapy
Limit IV therapy to 1-2 weeks, then transition to oral therapy once the patient is clinically stable and culture results confirm susceptibility 3. This recommendation is based on the OVIVA trial demonstrating non-inferiority of oral antibiotics after initial IV therapy for bone and joint infections 3.
For severe infections like endocarditis, the traditional approach used 4-6 weeks of IV therapy 1, but emerging evidence supports earlier oral transition. One study demonstrated successful outcomes with IV cloxacillin for an average of only 10 days followed by oral therapy 4.
Oral Step-Down Regimen
Transition to oral cloxacillin or dicloxacillin 500 mg every 6 hours (2 g/day total) with probenecid to enhance serum levels 4. The oral phase should continue for a total treatment duration of 4-6 weeks from infection onset 1, 2.
Key considerations for oral transition:
- Patient must be clinically stable with improving soft tissue signs
- Cultures should be negative
- Wounds should be dry (particularly important if rifampin will be added) 3
- Monitor serum bactericidal titers if available to ensure adequate oral absorption 4
Important Caveats and Monitoring
Renal Function Adjustments
Critical warning: Standard dosing recommendations do not account for renal impairment, leading to systematic overdosing in 83.9% of ICU patients 5. Patients with creatinine clearance <10 mL/min are at highest risk for overdosing and neurological toxicity (persistent coma, delirium) 5.
For patients with renal impairment, consider:
- Therapeutic drug monitoring targeting trough concentrations of 20-50 mg/L 5, 6
- Dose reduction based on GFR: a nomogram suggests doses ranging from 3.5-13.1 g/day for GFR 20-125 mL/min 6
Continuous vs. Intermittent Infusion
Continuous infusion oxacillin may improve microbiological cure rates (94% vs 79%, P=0.03) compared to intermittent dosing 7. After a loading dose of 25 mg/kg, continuous infusion of 160 mg/kg/day maintains therapeutic levels more consistently 8.
Combination Therapy Considerations
For implant-related infections with retained hardware, add rifampin 300-450 mg orally twice daily after debridement and once wounds are dry, combined with a fluoroquinolone (ciprofloxacin or levofloxacin preferred) for 3-6 months total 9. Never use rifampin as monotherapy due to rapid resistance emergence 3, 9.
Monitoring Requirements
- Gentamicin (if added for first 3-5 days): Monitor renal function and otic toxicity 1, 10
- Oxacillin/cloxacillin: Monitor for thrombophlebitis with IV administration, particularly in elderly 2
- Hepatotoxicity: Monitor liver enzymes periodically
- Consider therapeutic drug monitoring in critically ill patients or those with renal impairment 5, 6
Treatment Duration by Infection Type
- Uncomplicated bacteremia: 14 days minimum 2
- Native valve endocarditis: 4-6 weeks 1, 10
- Prosthetic valve endocarditis: 6-8 weeks 1
- Osteomyelitis: 6 weeks minimum 3, 2
- Prosthetic joint infection with retained hardware: 3-6 months (with rifampin combination) 9
The evidence strongly supports early oral transition after initial IV stabilization, which reduces hospitalization costs and complications while maintaining equivalent efficacy 3, 4. However, this approach requires careful patient selection, ensuring clinical stability and appropriate monitoring.